NCT02654132 : Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab ( ELOQUENT-3)
ELOQUENT-3 trial NCT02654132: Phase 2: An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without...
Dec 8, 2016
308
NCT02675452: Phase 1 - AMG 176 First in Human Trial in RRMM / Relapsed or Refractory AML
AMG 176 NCT02675452: Phase 1 - AMG 176 First in Human Trial in RRMM / Relapsed or Refractory AML AMG 176 First in Human Trial in...
Dec 8, 2016
233
NCT02693535: Phase 2: TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs
NCT02693535: Phase 2: TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a...
Dec 8, 2016
94
Myeloma Canada: Patient Handbook - Myeloma and the Kidney
Myeloma Canada: Patient Handbook - Myeloma and the Kidney https://myeloma.ca/pixms/uploads/serve/ckeditor/mc_kidney_booklet_en_02_2017_we...
Dec 8, 2016
57
International Myeloma Working Group Recs for Diagnosis & Manag. of Myeloma-Related Renal Impairment
J Clin Oncol; 2016 May International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal...
Dec 8, 2016
36
FDA Approved for RRMM: Daratumumab + Revlimid & Dex AND Daratumumab + Velcade & Dex
On November 21, 2016, the U.S. Food and Drug Administration approved daratumumab (DARZALEX, Janssen Biotech, Inc.) in combination with...
Dec 7, 2016
178
NCT02969837: Phase 2 - Study of Initial Treatment With Elotuzumab, Carfilzomib, Len and Dex NDMM
NCT02969837: Phase 2 - Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma...
Dec 7, 2016
174
NCT02786511: Longterm Follow-up of Subjects Treated With bb2121
NCT02786511: Longterm Follow-up of Subjects Treated With bb2121 NCT02786511: Longterm Follow-up of Subjects Treated With bb2121 This is a...
Dec 3, 2016
177
A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma
A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma Establish the MTD of Lintuzumab-Ac225 as monotherapy...
Dec 1, 2016
65
NCT02541383: Phase 3 - Bortezomib, thalidomide, dex +/-Daratumumab before & after ASCT (CASSIOPEIA)
The CASSIOPEIA trial IFM / HOVON IFM 2015-01 HOVON HO131 MM Newly Diagnosed Multiple Myeloma A Study to Evaluate Daratumumab in...
Dec 31, 2015
706
NCT02336815 : Phase 2 - Selinexor Treatment of Refractory Myeloma (STORM)
STORM Selinexor Treatment of Refractory Myeloma (STORM) This is a Phase 2b, single-arm, open-label, multicenter study of selinexor 80 mg...
Dec 30, 2015
225
NCT02332850: Phase Ib Study of SAR650984 With Carfilzomib for Treatment of Relapsed Multiple Myeloma
Multiple Myeloma Research Consortium NCT02332850: Phase Ib Study of SAR650984 With Carfilzomib for Treatment of Relapsed Multiple Myeloma...
Dec 23, 2015
175
Cancer Therapy: Oral Medication Basics: Information for Patients and Families (Targeted Therapy)
Cleveland Clinic Cancer Therapy: Oral Medication Basics: Information for Patients and Families (Targeted Therapy)
Dec 20, 2015
21
Cancer Therapy: Oral Medication Basics: Information for Patients and Families (Chemotherapy)
Cleveland Clinic: Cancer Therapy: Oral Medication Basics: Information for Patients and Families (Chemotherapy)
Dec 20, 2015
137
Myeloma UK - Myeloma Animations Series: Proteasome inhibitors in myeloma
Myeloma UK - Myeloma Animations Proteasome inhibitors in myeloma Learn More: https://www.myeloma.org.uk/
Dec 19, 2015
92
NCT02538198: Phase 2 - Lenalidomide Maintenance in Plasma Cell Myeloma
NCT02538198: Phase 2 - Lenalidomide Maintenance in Plasma Cell Myeloma This is a Phase 2 study to assess the good and bad effects of...
Dec 19, 2015
118
Myeloma UK - Myeloma Animations Series: Immunotherapy in myeloma
Myeloma UK - Myeloma Animations Immunotherapy in myeloma Learn More: https://www.myeloma.org.uk/
Dec 19, 2015
116
NCT02415413: Phase 2 - Carfilzomib in Patients Under 65 With High Risk Smoldering MM GEM-CESAR trial
GEM-CESAR trial PETHEMA/GEM Spanish Myeloma Group GEM (Grupo Español de Mieloma)/PETHEMA (Programa para el Estudio de la Terapéutica en...
Dec 19, 2015
471
FDA Approved for RRMM: Elotuzumab (Empliciti) with lenalidomide and dexamethasone (Rd)
11/30/2015: Bristol-Myers Squibb and AbbVie Receive FDA Approval of Empliciti™ (elotuzumab) for the Treatment of Patients with Multiple...
Dec 19, 2015
34
NCT02612779: Phase 2 - Elotuzumab in Combination With Pomalidomide and Low dose Dex Vs Nivo/Elo
Study of elotuzumab in combination with pomalidomide and low dose dexamethasone (EPd Cohort) and elotuzumab in combination with nivolumab...
Dec 18, 2015
182
NCT02343042: Phase 1/2 - Selinexor and Backbone Treatments of Multiple Myeloma Patients (STOMP)
STOMP Selinexor and Backbone Treatments of Multiple Myeloma Patients (STOMP) This study will independently assess the efficacy and safety...
Dec 18, 2015
451
FDA Approved for RRMM: Panobinostat (Farydak) Capsules + Bortezomib (Velcade) and Dexamethasone
FDA Approved for RRMM: Panobinostat (Farydak) Capsules + Bortezomib(Velcade) and Dexamethasone Relapsed & Refractory Multiple Myeloma...
Dec 17, 2015
90
Myeloma UK - Myeloma Animations Series: Genetic causes of myeloma
Myeloma UK - Myeloma Animations Genetic causes of myeloma Learn More: https://www.myeloma.org.uk/
Dec 17, 2015
47
Nature Videos: Tumour immunology and immunotherapy
Nature Videos: Tumour immunology and immunotherapy https://www.nature.com/
Dec 15, 2015
104